Summit managers' stock sales prompted by confidential Visx documents, shareholder's suit claims.
This article was originally published in The Gray Sheet
SUMMIT EXECS' STOCK SELL-OFF ALLEGEDLY PROMPTED BY VISX DOCUMENTS, according to a lawsuit filed by Summit shareholder Richard Pearl Aug. 2 in the U.S. District Court for Massachusetts. The suit, which seeks class action status, alleges that stock sales made by five Summit Technology executives between late November 1995 and May were prompted by Muller's receipt on Nov. 24, 1995 of confidential documents leaked from FDA.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.